Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
– Positive ENLIGHTEN 2 Phase 3 results announced in June 2025 propel business activities in manufacturing, regulatory strategy and ENLIGHTEN clinical dataset analysis to advance path forward for LY...
What are the potential upside or downside scenarios if regulatory feedback on LYR-210 is delayed or requires additional studies?
How does the Phase 3 success impact the risk profile and discount rate used in DCF models for Lyra Therapeutics?
Are there any upcoming catalyst events (e.g., FDA meetings, data releases, partnership announcements) that could drive short‑term stock movement?
9 days ago